Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Gets Price Target Bump from Cantor Fitzgerald

Posted by George Bondi on Nov 3rd, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its target price hoisted by stock analysts at Cantor Fitzgerald from $595.00 to $619.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has an “overweight” rating on the pharmaceutical company’s stock. Cantor Fitzgerald‘s price objective would suggest a potential upside of 11.90% from the stock’s previous close.

Several other analysts have also recently commented on VRTX. Barclays upped their target price on Vertex Pharmaceuticals from $615.00 to $617.00 and gave the company an “overweight” rating in a report on Wednesday, August 5th. JPMorgan Chase & Co. assumed coverage on shares of Vertex Pharmaceuticals in a research note on Friday, September 11th. They issued an “overweight” rating and a $560.00 target price for the company. Canaccord Genuity Group increased their target price on Vertex Pharmaceuticals from $436.00 to $442.00 and gave the company a “hold” rating in a research note on Tuesday, August 4th. The Goldman Sachs Group set a $653.00 target price on Vertex Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, September 1st. Finally, Morgan Stanley assumed coverage on Vertex Pharmaceuticals in a research note on Tuesday, September 1st. They issued an “overweight” rating and a $665.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $580.70.

Check Out Our Latest Stock Report on Vertex Pharmaceuticals

Vertex Pharmaceuticals Trading Down 1.0%

Shares of NASDAQ VRTX opened at $553.15 on Tuesday. Vertex Pharmaceuticals has a 1-year low of $403.16 and a 1-year high of $568.67. The business’s 50 day moving average is $523.32 and its 200-day moving average is $479.96. The firm has a market cap of $140.39 billion, a P/E ratio of 32.20, a price-to-earnings-growth ratio of 2.54 and a beta of 0.28.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.06). Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%. The firm had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same quarter in the prior year, the business posted $4.80 EPS. The business’s revenue was up 11.8% on a year-over-year basis. Analysts forecast that Vertex Pharmaceuticals will post 16.74 EPS for the current year.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Community Financial Services Group LLC bought a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at approximately $26,000. Meeder Asset Management Inc. purchased a new stake in Vertex Pharmaceuticals during the second quarter worth $26,000. MADDEN SECURITIES Corp purchased a new position in shares of Vertex Pharmaceuticals in the 3rd quarter worth approximately $26,000. Elevation Wealth Partners LLC boosted its holdings in Vertex Pharmaceuticals by 103.7% in the second quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 28 shares in the last quarter. Finally, Pingora Partners LLC acquired a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $32,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

Positive Sentiment: Third-quarter revenue rose 11.8% year over year to $3.44 billion, exceeding the $3.42 billion analyst estimate. Growth was supported by continued strength in the cystic fibrosis franchise and increasing contributions from newer products, including CASGEVY and JOURNAVX. Vertex Q3 2026 Earnings Call Transcript
Positive Sentiment: Vertex raised its full-year 2026 revenue guidance, citing broad-based portfolio growth and the successful completion of its Crinetics Pharmaceuticals acquisition. Management also highlighted its advancing pipeline and a developing nephrology franchise as future growth opportunities. Vertex Reports Third Quarter 2026 Financial Results
Neutral Sentiment: The transition from Trikafta to newer cystic fibrosis treatment Alyftrek continued to expand the franchise, while the ramp-up of recently launched medicines may diversify Vertex’s long-term revenue base. However, the company is investing heavily in these launches and in the Crinetics deal. Vertex Spends Its CF Growth on New Launches
Negative Sentiment: Adjusted earnings were $4.76 per share, below analyst expectations of approximately $4.82–$4.92 and down from $4.80 a year earlier. The shortfall reflects increased spending on new product launches, research and development, and the Crinetics acquisition, limiting profit growth despite higher sales. Vertex Misses Q3 Earnings Estimates
Negative Sentiment: Although full-year revenue guidance was increased, reports characterized the improvement as a light hike that fell short of some investor expectations. That combination—an earnings miss and limited guidance upside—helped pressure the stock despite the revenue beat. Vertex Yo-Yos on Mixed Third-Quarter Report

Vertex Pharmaceuticals Company Profile

(Get Free Report)

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.